TABLE 5.

Composition of Apo moieties in lipoproteins of ALL survivors compared with age- and gender-matched controls using SDS-PAGE

	Composition in Apos
Lipoprotein	B-100	A-IV	E	A-I	Cs	A-II	Ratio (A-I/A-II)
	Percentage of total content
VLDL (1.006 g/ml)
Controls	49.55 ± 3.12	16.41 ± 1.91	10.09 ± 1.16	10.82 ± 1.59	13.23 ± 1.61	—	—
ALL survivors	42.88 ± 1.92	13.88 ± 1.11	14.46 ± 0.83a	11.65 ± 1.00	17.00 ± 1.33	—	—
No dyslipidemia	44.08 ± 2.51	14.77 ± 1.07	13.69 ± 1.25	11.00 ± 1.21	16.38 ± 1.71	—	—
Dyslipidemia	41.69 ± 2.98	13.00 ± 1.97	15.23 ± 1.09a	12.31 ± 1.61	17.62 ± 2.09	—	—
IDL (1.019 g/ml)
Controls	79.18 ± 2.30	4.68 ± 0.51	4.75 ± 0.60	4.69 ± 0.82	6.54 ± 0.86	—	—
ALL survivors	57.81 ± 3.68b	9.96 ± 0.68b	8.35 ± 0.59b	8.15 ± 0.94c	15.81 ± 2.25a	—	—
No dyslipidemia	59.08 ± 4.41b	10.69 ± 0.92b	8.00 ± 0.88a	6.85 ± 1.08	15.31 ± 3.26	—	—
Dyslipidemia	56.54 ± 6.07b	9.23 ± 0.99b	8.69 ± 0.83b	9.46 ± 1.49c	16.31 ± 3.22a	—	—
LDL (1.063 g/ml)
Controls	65.77 ± 1.53	3.27 ± 0.21	4.32 ± 0.31	23.23 ± 1.64	3.55 ± 0.30	—	—
ALL survivors	68.73 ± 2.26	3.88 ± 0.36	4.50 ± 0.26	19.08 ± 2.13	3.89 ± 0.49	—	—
No dyslipidemia	67.69 ± 2.97	3.46 ± 0.51	4.23 ± 0.23	23.69 ± 2.79	2.85 ± 0.52	—	—
Dyslipidemia	71.62 ± 2.94c	4.31 ± 0.49	4.77 ± 0.47	14.46 ± 2.74a,d	4.92 ± 0.75e	—	—
HDL3 (1.210 g/ml)
Controls	—	1.10 ± 0.07	1.58 ± 0.10	83.29 ± 0.81	4.67 ± 0.35	9.52 ± 0.82	10.10 ± 0.76
ALL survivors	—	1.26 ± 0.09	1.78 ± 0.09	83.04 ± 0.63	5.54 ± 0.43	8.58 ± 0.49	10.58 ± 0.63
No dyslipidemia	—	1.44 ± 0.14c	1.78 ± 0.16	83.15 ± 0.84	5.31 ± 0.63	8.39 ± 0.63	10.54 ± 0.77
Dyslipidemia	—	1.09 ± 0.09e	1.79 ± 0.10	82.92 ± 0.96	5.77 ± 0.59	8.77 ± 0.78	10.62 ± 1.03
HDL2 (1.125 g/ml)
Controls	—	1.27 ± 0.14	3.33 ± 0.33	72.23 ± 0.97	13.09 ± 0.92	10.14 ± 0.85	7.31 ± 0.65
ALL survivors	—	0.89 ± 0.033a	3.85 ± 0.41	68.50 ± 1.11c	11.88 ± 0.74	14.54 ± 1.21c	5.59 ± 0.47a
No dyslipidemia	—	0.80 ± 0.04	2.64 ± 0.24	69.31 ± 1.76	10.46 ± 0.67	16.31 ± 1.88a	4.99 ± 0.63a
Dyslipidemia	—	0.97 ± 0.04d	4.73 ± 0.59c,d	67.69 ± 1.40c	13.31 ± 1.22	12.77 ± 1.44	6.19 ± 0.67

Data are expressed as percentage of total Apo content ± SEM. Composition in Apos was assessed in VLDL, IDL, LDL, HDL₃, and HDL₂ of n = 26 ALL survivors and n = 22 gender- and age-matched controls. ALL survivors were stratified in two groups according to their dyslipidemia status as described in the Materials and Methods (n = 13/group). Apo distribution was analyzed using SDS-PAGE (4–20% gradient).

^aP < 0.01 versus controls.

^bP < 0.001 versus controls.

^cP < 0.05 versus controls.

^dP < 0.01 versus ALL survivors without dyslipidemia.

^eP < 0.05 versus ALL survivors without dyslipidemia.